Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Semaglutid untuk pengelolaan berat badan pada obesitas

Penilaian teknologi kesehatan PTK-A10BJ06 Draf untuk telaah Diperbarui 12 Juni 2026

1. Latar belakang klinis

Gambaran penyakit

Uraian berikut tersedia dalam bahasa Inggris.

Obesity is a chronic, relapsing, progressive disease defined by excess adiposity that impairs health, conventionally indexed by a body-mass index (BMI) of 30 kg/m2 or higher, with lower ethnicity-adjusted Asian cut-points of 25 to 27 kg/m2 reflecting higher cardiometabolic risk at a given BMI. It is not simply a lifestyle state but a dysregulation of energy homeostasis driven by hypothalamic, gut-hormone (including GLP-1) and adipose-tissue signalling, with strong genetic and obesogenic-environment contributions. Pathophysiologically, expanded and ectopic fat promotes chronic low-grade inflammation, insulin resistance, dyslipidaemia and hypertension, mechanistically linking obesity to type 2 diabetes, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, obstructive sleep apnoea, osteoarthritis and several cancers (WHO 2024). Clinically it matters as a modifiable upstream driver of the non-communicable disease burden: even modest, sustained weight loss of 5 to 15% measurably improves glycaemia, blood pressure and cardiovascular risk, yet lifestyle-only approaches rarely achieve or maintain this magnitude, defining a large therapeutic gap.

Epidemiologi

Uraian berikut tersedia dalam bahasa Inggris.

The global burden is vast and rising. WHO estimated that in 2022 about 2.5 billion adults were overweight, including over 890 million living with obesity, equating to roughly 43% of adults overweight and 16% with obesity, with obesity prevalence more than doubling since 1990 (WHO 2024). The GBD 2021 forecasting study estimated that 2.11 billion adults (about 1.00 billion men and 1.11 billion women) had overweight or obesity in 2021, projected to reach 3.80 billion by 2050 (GBD 2021 Obesity Collaborators 2025); high BMI was associated with an estimated 3.71 million deaths and 128.5 million DALYs in 2021 (Ng et al., eClinicalMedicine 2024). In Indonesia, Riskesdas documented adult obesity (BMI >=27) rising from 10.5% (2007) to 14.8% (2013) and 21.8% (2018), higher in women (29.3%) than men (14.5%), with central obesity around 31% and provincial peaks such as North Sulawesi (about 30%) (Kemenkes Riskesdas 2018). With an adult population exceeding 190 million, this implies tens of millions affected, concentrated in urban and higher-income strata, and high BMI ranks among the leading risk factors for death and disability nationally, underpinning Indonesia's surging type 2 diabetes and cardiovascular burden.

Terapi standar saat ini

Uraian berikut tersedia dalam bahasa Inggris.

Standard care begins with structured lifestyle modification, namely reduced-calorie diet, increased physical activity and behavioural support, typically delivered within tiered weight-management services internationally and escalating to multidisciplinary specialist care. Pharmacotherapy is added when lifestyle alone is insufficient. In Indonesia, the Kemenkes obesity guideline for primary health care (2021) and PB PAPDI/PERKENI guidance endorse lifestyle-first management, with orlistat 120 mg three times daily and the GLP-1 receptor agonist liraglutide 3 mg as adjuncts, reserving surgery for severe cases (Kemenkes 2021). Limitations are substantial: lifestyle programmes are weakly resourced and rarely sustained; orlistat is poorly tolerated (gastrointestinal effects) with modest efficacy; liraglutide requires daily injection and is costly; and bariatric surgery is concentrated in a few tertiary centres. Community-level response rests on puskesmas counselling and Posbindu PTM screening. Critically, none of these agents is reimbursed under JKN, so most pharmacological treatment is self-financed, restricting access to affluent urban patients.

Status regulasi dan penjaminan

Uraian berikut tersedia dalam bahasa Inggris.

The US FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management on 4 June 2021, the first new anti-obesity agent since 2014 (FDA 2021), followed by EMA marketing authorisation in 2022 and a positive NICE recommendation in TA875 (March 2023), which restricts use to specialist weight-management services for a maximum of two years (NICE 2023). It is indicated for adults with BMI >=30, or >=27 with a weight-related comorbidity, alongside diet and physical activity. In Indonesia, BPOM has registered Wegovy for weight management in adults, with public assessment reports documenting approval activity across 2024 to 2025, making it the only BPOM-approved injectable anti-obesity GLP-1 of its class (BPOM 2024). Critically, anti-obesity medicines including semaglutide are not listed in the Formularium Nasional (Fornas) and are therefore not reimbursed under JKN/BPJS Kesehatan; access is via private prescription and full out-of-pocket payment, a key affordability and equity constraint. No Indonesian HTA appraisal has yet been published.

2. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Semaglutid 2,4 mg per minggu disertai program pengelolaan berat badanRp 140,2 juta16,13433,25
program pengelolaan berat badan dengan diet, latihan fisik, dan dukungan perilakuRp 71,7 juta15,36231,71
SelisihRp 68,5 juta0,772-

3. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
050100150-0,500,000,501,001,502,00Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta96,1%

4. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-40-2002040interventions semaglutide 2 4mg weekly plus lifestyle drug cost idr per courseinterventions semaglutide 2 4mg we...utility values normal glucose toleranceutility values normal glucose tole...interventions specialist weight management lifestyle transition rate multipliers normal glucose tolerance to post cv eventinterventions specialist weight ma...transition rates annual normal glucose tolerance to deadtransition rates annual normal glu...transition rates annual non diabetic hyperglycaemia to type2 diabetestransition rates annual non diabet...utility values type2 diabetesutility values type2 diabetesinterventions specialist weight management lifestyle transition rate multipliers non diabetic hyperglycaemia to type2 diabetesinterventions specialist weight ma...interventions semaglutide 2 4mg weekly plus lifestyle transition rate multipliers normal glucose tolerance to post cv eventinterventions semaglutide 2 4mg we...transition rates annual non diabetic hyperglycaemia to normal glucose tolerancetransition rates annual non diabet...transition rates annual non diabetic hyperglycaemia to post cv eventtransition rates annual non diabet...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

5. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (40 yr)0,772Rp 68,5 jutaRp 88,8 juta
5-year horizon0,028Rp 84,1 jutaRp 3,0 miliar
10-year horizon0,078Rp 80,9 jutaRp 1,0 miliar
20-year horizon0,267Rp 75,0 jutaRp 281,3 juta
0% discount rate1,661Rp 59,0 jutaRp 35,5 juta
5% discount rate0,491Rp 70,9 jutaRp 144,5 juta
Full weight-regain after 2-year stop (diabetes/CV benefit reverts toward comparator)0,853Rp 67,1 jutaRp 78,7 juta
Lower Asian BMI thresholds expand a lower-baseline-risk population (CV/diabetes onset x0.85)0,717Rp 69,5 jutaRp 96,9 juta
High Indonesian prediabetes-to-diabetes progression (x1.4)0,911Rp 66,0 jutaRp 72,5 juta
BPJS-negotiated price 40% below private list (semaglutide acquisition x0.6)0,772Rp 31,8 jutaRp 41,2 juta

6. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0020%).

Luaran pembandingPrediksi modelData terbitSumber
Annual progression from non-diabetic hyperglycaemia (prediabetes/IGT) to type 2 diabetes, lifestyle/comparator arm7,2%7,5%Tabak AG et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379(9833):2279-2290 - ~5-10%/yr IGT
Annual reversion of non-diabetic hyperglycaemia to normoglycaemia, lifestyle/comparator arm20,0%20,0%STEP 1 placebo arm ~47.8% reverted to normoglycaemia at 68wk (Perreault L et al. Diabetes Care 2022;45:2396-2405); long-
Cumulative cardiovascular event incidence at 10 years from normal glucose tolerance, lifestyle/comparator arm6,0%8,0%SELECT (Lincoff AM et al. NEJM 2023;389:2221-2232): primary MACE 8.0% in the placebo arm over mean ~3.3 yr in an obese/o

7. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • TA875 recommends semaglutide only within specialist weight-management services and for a maximum of 2 years; the Indonesia model mirrors this constrained pathway.
  • Asian/Indonesian BMI risk thresholds (overweight >=23, obesity >=25-27) may justify lower BMI cut-offs than UK criteria, expanding the eligible pool but potentially lowering baseline absolute risk and worsening the ICER.
  • A 6-month stopping rule for <5% weight loss should be implemented to preserve cost-effectiveness, consistent with STEP/TA875.
  • Semaglutide is BPOM-registered (2024) but NOT in Fornas; current access is fully out-of-pocket, a major equity concern that HTA should adjudicate before any reimbursement.
  • Budget impact is dominated by chronic, high-acquisition-cost treatment in a large, fast-growing obese population; eligibility narrowing (e.g., to high-CV-risk SELECT-like subgroups) materially improves affordability.